Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma. Issue 19 (21st August 2020)

• Record Type: Journal Article
• Authors: Yu, Yiyang; Zhang, Hongliang; Ren, Tingting; Huang, Yi; Liang, Xin; Wang, Wei; Niu, Jianfang; Han, Yu; Guo, Wei
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 19(2020)
• Page Start: 11230
• Page End: 11242
• Publication Date: 2020-08-21
• Subjects: bioinformatics -- immunotherapy -- osteosarcoma -- prognostic; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.15687
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Osteosarcoma is the most common primary malignant bone tumour predominantly occurring in children and adolescents with a high tendency of local invasion and early metastases. Currently, tumour immune microenvironment (TME) is becoming the focus of studying of malignant tumours.. However, no sound evidence shows a specific immune molecular target in osteosarcoma. We downloaded the gene expression profile and clinical data of osteosarcoma from the TARGET portal, and extracted and normalized via R software. Then, the immune cell infiltration assessed by CIBERSORT and ESTIMATE algorithms. Three survival‐related immune cells and immune score were obtained via Kaplan‐Meier survival analysis, and 232 immune‐related genes were obtained as candidate genes. Enrichment and protein‐protein interaction co‐expression analyses were performed to identify 13 hub genes. Lastly, a seven gene prognostic signature was identified by univariate and multivariate Cox regression analyses. More importantly, our validations and TIMER algorithm suggested this immune‐related prognostic signature a good predictive tool. Our findings have provided novel insights that could demonstrate new targets of immunotherapy in osteosarcoma.